INDICATION(S)
The GCarbo regimen ( Table 1 ) has been studied in metastatic bladder cancer [1] [2] [3] [4] [5] [6] and is recommended as an alternative regimen to first-line chemotherapy in metastatic disease. 7 The GCarbo regimen has also been studied as perioperative chemotherapy, specifically neoadjuvant chemotherapy, in locally advanced bladder cancer prior to cystectomy. 8, 9 Current bladder cancer guidelines, however, recommend against the substitution of carboplatin for cisplatin in the setting of perioperative chemotherapy and suggest consideration of split-dose administration of cisplatin for patients with renal dysfunction, although efficacy of this adjustment remains unproven. 7
CARBOPLATIN DOSE CALCULATION
Carboplatin doses are commonly calculated using an equation based on the method of Calvert et al. 10 Calvert's group showed that the carboplatin dose in milligrams can be calculated using a desired area under the time versus concentration curve (AUC) and the patient's glomerular filtration rate (GFR). Calvert measured GFR by clearance of chromium-51-EDTA. The equation is: carboplatin dose (mg) = AUC x [GFR + 25].
If radiopharmaceutical clearance is not used to measure GFR, creatinine clearance (CrCl) estimated by the Cockcroft-Gault method 11 
DRUG ADMINISTRATION
A. Gemcitabine 1. In the studies reviewed, gemcitabine was given as a 30-minute intravenous (IV) infusion. 1-4 2. Infusion times greater than 60 minutes have been associated with increased grade 3 or 4 hematologic toxicity due to accumulation of the active metabolite gemcitabine triphosphate. 21 B. Carboplatin: In the studies reviewed, carboplatin was given as a 30-1 to 60-minute 2-4 IV infusion.
SUPPORTIVE CARE A. Acute and Delayed Emesis Prophylaxis:
The GCarbo regimen is predicted to cause vomiting in 30% to 90% of patients on day 1 and in 10% to 30% of patients on day 8 and day 15. 22,23 The studies reviewed reported nausea in 14%, 6 nausea and vomiting in 10% to 47%, 2,8,9 grade 3 to 4 nausea and vomiting in 7% to 65%, 2,5 vomiting in 32%, 3 and grade 3 or 4 vomiting in 7% of patients. 3 Appropriate acute emesis prophylaxis includes a serotonin antagonist and a corticosteroid plus or minus a neurokinin antagonist in selected patients. 22, 23 One of the following regimens is suggested: The antiemetic therapy should continue for at least 2 days after day 1. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid or a steroid and dopamine antagonist combination most appropriate for follow-up therapy. 24 One of the following regimens is suggested: 1. Dexamethasone 8 mg PO once daily for 2 days, ± metoclopramide 0.5 to 2 mg/kg PO every 4 to 6 hours, ± diphenhydramine 25 to 50 mg PO every 6 hours if needed, starting on day 2 of GCarbo. 2. Dexamethasone 8 mg PO once daily for 2 days, ± prochlorperazine 10 mg PO every 4 to 6 hours, ± diphenhydramine 25 to 50 mg PO every 6 hours if needed, starting on day 2 of GCarbo. 3. Dexamethasone 8 mg PO once daily for 2 days, ± promethazine 25 to 50 mg PO every 4 to 6 hours, ± diphenhydramine 25 to 50 mg PO every 6 hours if needed, starting on day 2 of GCarbo. If a neurokinin antagonist is used on day 1 of GCarbo, then aprepitant 80 mg PO once daily for 2 days should be added to one of the regimens above, starting on day 2 of GCarbo.
The GCarbo regimen is predicted to cause vomiting in 10% to 30% of patients on days 8 and 15. 22 On days 8 and 15, a single dose of one of the following premedications is suggested: dexamethasone 12 mg PO or metoclopramide 10 to 40 mg PO or prochlorperazine 10 mg PO. A single dose of an oral serotonin antagonist may also be considered.
B. Breakthrough Nausea and Vomiting 22,23 :
Patients should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is suggested: 
C. Hematopoietic Growth Factors:
Accepted practice guidelines and pharmaco economic analysis suggest that antineoplastic regimens have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 25 In the trials reviewed, neutropenia was reported in 50% to 100% 1-3,6,8,9 of patients and grade 3 to 4 neutropenia in 7% to 70% 1-6,8,9 of patients. Febrile neutropenia was reported in 3% to 25% of patients. 1, 3, 4, 8, 9 Prophylactic use of CSFs is recommended with this regimen.
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute Common Terminology Criteria for Adverse Events (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but they make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Edema (all grades) 17%, 3 (grade 3 or 4) 7%. 3 B. Constitutional: Asthenia (all grades) 73%, 3 (grades 3 or 4) 19% 3 ; fatigue (all grades) 6% to
